Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C
This is a long-term evaluation follow-up study of neurocognitive performance and emotional state in patients with chronic hepatitis C infection and a former (peg)interferon alfa-2b-based therapy.
M.R. Kraus, G. Teuber, NN, NN (MPsych), M. Scheurlen
- Neurocognitive and psychiatric changes induced by interferon alfa-2b therapy in patients with chronic hepatitis C - are they fully reversible in long-term follow-up after the end of antiviral treatment?
- At least 12 months after the end of antiviral treatment - are neurocognitive and mood-related parameters even significantly improved as compared to pretreatment values? Is this possibly only true of patients with successful virus eradication?
- At least 12 months after the end of antiviral treatment, is there a significant difference between patients with and without sustained virological response with respect to neurocognitive performance, emotional state and quality of life?
- In the absence of clinically significant liver damage in patients with chronic hepatitis C - does the mere presence of the hepatitis C virus have any significant influence on neurocognitive or attentional performance?
- Does the study data support an additional indication for antiviral therapy in chronic hepatitis C? In the case of successful virus eradication, emotional state and - above all - is neurocognitive performance significantly improved even in the absence of severe liver damage?
Hepatitis C, Chronic
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C Infection and a Former (Peg)Interferon Alfa-2b-Based Therapy|
|Study Start Date:||July 2005|
|Study Completion Date:||August 2008|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00227149
|Med. Klinik und Poliklinik II, University of Wuerzburg|
|Wuerzburg, Germany, 97070|
|Principal Investigator:||Michael R. Kraus, MD, PhD||Med. Klinik und Poliklinik II, University of Wuerzburg|